Avalo Therapeutics Inc. (NASDAQ:AVTX) finished Thursday with a subtraction of $0.0 to close at $0.10, a downside of -6.34 percent. An average of 22,179,680 shares of common stock have been traded in the last five days. There was a fall of -$0.0506 in the past week, and it reached a new high 13 times over the past 12 months. The last 20 days have seen an average of 9,427,200 shares traded, while the 50-day average volume stands at 5,417,700.
AVTX stock has decreased by -58.44% in the last month. The company shares reached their 1-month lowest point of $0.0866 on 08/22/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $0.09 and a high of $7.00 in 52 weeks. It has reached a new high 4 times so far this year and lost -98.10% or -$4.9441 in price. In spite of this, the price is down -98.63% from the 52-week high.
Insider Transactions
AVTX stock investors should be aware that Avalo Therapeutics Inc. (AVTX) stock had its last reported insider trading activity 59 days ago on Jun 27. In this transaction, the insider spent $486,888. 10% Owner, ARMISTICE CAPITAL, LLC, disposed of 2,746,138 shares at a price of $0.61 on Jun 26. The insider now owns more than $1,682,010 worth of shares.
Valuation Metrics
Avalo Therapeutics Inc. (AVTX) stock’s beta is 1.34. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.14.
Financial Health
The quick ratio of Avalo Therapeutics Inc. for the three months ended June 29 was 0.30, and the current ratio was 0.30, indicating that the company is not able to meet its debt obligations. Avalo Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -206.49%. Its gross profit as reported stood at $14.62 million compared to revenue of $18.05 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Avalo Therapeutics Inc.’s return on assets was -76.00%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$8.19 million in the quarter, while revenues of -$9.96 million were shrunk -58.61%. The analyst consensus anticipated Avalo Therapeutics Inc.’s latest quarter earnings to come in at -$0.8 per share, but it turned out to be -$0.59, a 26.30% surprise. For the quarter, EBITDA amounted to -$6.76 million. Shareholders own equity worth $20.25 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Avalo Therapeutics Inc. (AVTX) price momentum. RSI 9-day as of the close on 24 August was 25.93%, suggesting the stock is oversold, with historical volatility in this time frame at 194.51%.
As of today, AVTX’s price is $0.1035 -34.52% or -$0.0506 from its 5-day moving average. AVTX is currently trading -53.40% lower than its 20-day SMA and -94.51% lower than its 100-day SMA. However, the stock’s current price level is -97.41% below the SMA50 and -98.58% below the SMA200.
The stochastic %K and %D were 8.70% and 6.74%, respectively, and the average true range (ATR) was 0.0304. With the 14-day stochastic at 9.85% and the average true range at 0.0561, the RSI (14) stands at 27.03%. The stock has reached -0.0222 on the 9-day MACD Oscillator while the 14-day reading was at -0.0336.
Analyst Ratings
RBC Capital Mkts launched coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) in its analyst report released on September 24, 2021. The firm assigned the stock an Outperform rating.
